作为华仁药业全产业链布局的关键环节，肥东原料药生产基地的建设具有重要战略意义。近年来，医药 行业集采政策持续深化，产业链整合与成本管控成为企业核心竞争力的重要体现。华仁药业依托多年积 累的研发优势与产业经验，通过该基地的建设进一步完善"原料-制剂-包材"协同体系，将实现从上游原 料研发生产到下游制剂加工的全流程把控。通过工艺优化与精细化成本管控，公司产品的市场竞争力将 得到显著提升，为在集采背景下实现高质量发展奠定坚实基础。 2025年12月10日，华仁药业(300110.SZ)与肥东县人民政府正式签订原料药生产基地项目合作框架协 议。此次合作不仅标志着华仁药业"原料+制剂+包材"一体化战略的深度落地，更为肥东县生物医药产 业集群建设注入强劲动力，实现企业发展与地方经济的双赢格局。 据了解，该原料药生产基地项目选址于合肥循环经济示范园，规划用地约100亩。项目将严格遵循GMP 标准，建设现代化原料药生产线及配套设施，聚焦呼吸科、精麻科等领域的高附加值原料药研发与生 产。投产后，基地将形成规模化、智能化的生产能力，一方面为华仁药业自身制剂板块提供稳定、高品 质的原料供应，从源头保障制剂产品的质量与供应稳定性；另 ...

Core Viewpoint - The appointment of Jiang Ying as the new Secretary of the Board at Luoxin Pharmaceutical is a significant development, although her lack of experience in listed company secretary roles raises questions about her suitability for the position [3][6]. Company Overview - Luoxin Pharmaceutical, founded in 1988, has a diverse product range covering various medical fields including gastrointestinal diseases, pediatrics, oncology, and more [6]. - The company has experienced significant performance fluctuations in recent years, primarily due to the impacts of the COVID-19 pandemic, impairment provisions, and adjustments in financial liabilities [6]. Financial Performance - For the first half of 2025, Luoxin Pharmaceutical reported a revenue of 1.077 billion, a decrease of 14.45% year-on-year, while achieving a net profit attributable to shareholders of 17.695 million, marking a turnaround from losses in the previous year [6][7]. - The total revenue for the latest reporting period was 1.077 billion, with a total cost of 1.098 billion, resulting in an operating profit of 39.41 million, which is a 133.12% increase year-on-year [7]. - The net profit attributable to the parent company's shareholders was 17.695 million, reflecting a 119.95% increase compared to the same period last year [7]. Management Background - Jiang Ying, the newly appointed Secretary of the Board, has a strong academic background with dual degrees in Science and Economics from Peking University, as well as a Master's in Management from Peking University and a Master's in Finance from the University of Hong Kong [3][5]. - Prior to her appointment, Jiang Ying worked in various roles at Guotai Junan Securities, Everbright Pramerica Fund, and Guotai Fund, but lacks experience in listed company secretary positions [3][5].